Ophthalmology Journal

We're celebrating the American Glaucoma Society's 40th Anniversary! Dr. Emily Schehlein interviews three glaucoma luminaries, previous AGS Presidents, and guest editors for Ophthalmology Glaucoma's AGS 40th Anniversary special issue: Dr. Steven Gedde, Dr. Carla Siegfried, and Dr. Greg Skuta. Together they discuss the past, present, and future of the AGS, advancements in the treatment of glaucoma, and share their personal stories of mentorship and community within the society.
Read Ophthalmology Glaucoma's American Glaucoma Society 40th Anniversary supplement issue here:
https://www.ophthalmologyglaucoma.org/issue/S2589-4196(25)X0006-5
To find out more about the AGS, how to join, and get involved visit:
https://www.americanglaucomasociety.net/home
Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

It's our 100th episode! Dr. Rukhsana Mirza sits down with Drs. Aleksandra V. Rachitskaya and Kevin C. Allan to discuss their retrospective study using the TriNetX network to investigate the risk of neovascular age-related macular degeneration (AMD) in patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs). From their Ophthalmology Retina article, "Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study."
Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study. Allan, Kevin C. et al. Ophthalmology Retina. In press
Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial."
Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press.
Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

Our newest host and Social Media Editor, Dr. Rukhsana Mirza, interviews Dr. Phoebe Lin. Together, they discuss Dr. Lin's study on whether an intestinal microbial signature is associated with advanced age-related macular degeneration and the relationship between the microbiota and AMD genetic risk. From her Ophthalmology Science article, "Age-related Eye Disease Studies Supplements and Genetic Risk Score Are Crucial Determinants of Intestinal Microbial Alterations in Advanced Age-Related Macular Degeneration."
Dr. Phoebe Lin is an editor for Ophthalmology Science.
Age-related Eye Disease Studies Supplements and Genetic Risk Score Are Crucial Determinants of Intestinal Microbial Alterations in Advanced Age-Related Macular Degeneration, Dadgar, Neda et al. Ophthalmology Science, Volume 6, Issue 1.

Dr. Emily Schehlein is joined by Dr. Cecilia S. Lee and Dr Parisa Taravati, authors of "Elevated Intraocular Pressure Immediately after Cataract Surgery and Future Risk of Primary Open-Angle Glaucoma in the IRIS® Registry (Intelligent Research in Sight)." Together they discuss the associations between postoperative intraocular pressure after cataract surgery and the future risk of developing primary open-angle glaucoma in patients without prior glaucoma, glaucoma suspect, or ocular hypertension diagnoses.
Elevated Intraocular Pressure Immediately after Cataract Surgery and Future Risk of Primary Open-Angle Glaucoma in the IRIS® Registry (Intelligent Research in Sight). Gim, Nayoon et al. Ophthalmology Science, Volume 5, Issue 6.